Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 28

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 28
---
, “SHPH.” Subsequently, on August 27, 2024, we received
notice from Nasdaq that we had regained compliance with the Minimum Bid Price Requirement.

20

Item
1A. Risk Factors

An
investment in our securities involves a high degree of risk. You should carefully consider all of the risks described below, together
with the other information contained in this Annual Report on Form 10-K, including our financial statements and related notes elsewhere,
before making a decision to invest in our securities. If any of the following events occur, our business, financial condition and operating
results may be materially adversely affected. In that event, the trading price of our securities could decline, and you could lose all
or part of your investment. Additional risks and uncertainties not presently known to us or that
we currently believe to be immaterial may also adversely affect our business. Certain statements below are forward-looking statements.

Summary
Risk Factors

The
risks described under the heading “Risk Factors” beginning on page 25 of this Annual Report on Form 10-K may cause us not
to realize the full benefits of our strengths and/or may cause us to be unable to successfully execute all or part of our strategy. Some
of the more significant challenges we face include:

    ●
    Our
    ability to continue as a going concern in the near term is dependent upon us successfully raising additional equity or debt financing
    to fund our operations.

    ●
    Presently,
    there is substantial regulatory uncertainty surrounding future access to government funding of research activities, including access
    to grants awarded by the NIH which have traditionally provided support for certain of Shuttle Pharma’s research activities.

    ●
    Our
    success is primarily dependent on the successful development, regulatory approval and commercialization of our product candidates,
    all of which are in the early stages of development.

    ●
    We
    currently have no source of product sales revenue.

    ●
    We
    face competition from entities that have developed or may develop product candidates for our target disease indications, including
    companies developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies
    develop technologies or product candidates more rapidly than we do or their technologies, including delivery technologies, are more
    effective, our ability to develop and commercialize product candidates may be adversely affected.

    ●
    If
    we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or